Non-Hodgkin Lymphoma (NHL)

Latest News

The data suggest BsAbs are safe and effective in many patients with relapsed or refractory LBCL following CAR T-cell therapy. | Image credit: jarun011 - stock.adobe.com
Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

May 23rd 2025

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

May 16th 2025

Q&A with Andrew Evens, DO
Collaboration Advances Lymphoma Care: Andrew Evens, DO

May 12th 2025

Andrew Evens, DO
Expanding Resources, Clinical Knowledge to Enhance AYA NHL Care: Andrew Evens, DO

May 2nd 2025

Multigenerational | Image Credit: © DisobeyArt-stock.adobe.com
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older

April 16th 2025

Continuing Medical Education
View All
May 24th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
May 24th 2025

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer
May 24th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
May 24th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

More News

New Epcoritamab Data Show Strong Results in B-Cell Lymphomas
June 22nd 2023

New Epcoritamab Data Show Strong Results in B-Cell Lymphomas

Jared Kaltwasser
Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.
researchers in a lab
June 17th 2023

Epcoritamab Sparks Durable Responses in Phase 1/2 LBCL Trial

Jared Kaltwasser
At a median follow-up of 10.7 months, the overall response rate was 63.1%.
chest pain
June 16th 2023

Investigators Find DLBCL When Probing Apparent Intramural Hematoma

Jared Kaltwasser
The case report highlights the importance of considering diffuse large B-cell lymphoma (DLBCL) when evaluating patients with persistent periaortic fluid collections.
Epcoritamab Approval Expands Treatment Armamentarium for DLBCL
June 9th 2023

Epcoritamab Approval Expands Treatment Armamentarium for DLBCL

Mary Caffrey Rose McNulty
Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.
depressed older man sitting with his head in his hand
June 8th 2023

Preexisting Mental Health Disorders Worsen DLBCL Prognosis

Laura Joszt, MA
Patients with depression, anxiety, or both at the time of diagnosis of diffuse large B-cell lymphoma (DLBCL) have worse overall survival and lymphoma-specific survival.
science background
June 7th 2023

Review: Advances in the Understanding of DLBCL Immunology Could Spark Novel Therapies

Jared Kaltwasser
New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.
FDA approved
May 19th 2023

Epcoritamab Approved by FDA to Treat R/R DLBCL

Mary Caffrey
Approval for the T-cell–engaging bispecific antibody came today from the FDA.
ASH 2022: Bispecific Antibodies
February 4th 2023

ASH 2022: Bispecific Antibodies

Mary Caffrey Hayden E. Klein
Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.
Graphic with the words "Top 5 Clinical Spotlight Interviews of 2022"
December 29th 2022

Top 5 Clinical Spotlight Interviews of 2022

AJMC Staff
Throughout 2022, expert interviews on clinical topics covered cytogenetics in multiple myeloma, access to better treatments in diffuse large B-cell lymphoma, and challenges with devices in chronic obstructive pulmonary disease.
<1234

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo